Global Markets for Orphan Drugs
オーファンドラッグの世界市場
Report Highlights
The global market for orphan drugs is expected to increase from $233.9 billion in 2023 to $415.2 billion by the end of 2028, with a compound annual growth rate (CAGR) of 12.2% during the forecast period of 2023-2028.
Report Scope:
The scope of this study includes orphan drugs used in the global pharmaceutical markets. This report analyzes the therapeutic applications of orphan drugs in rare and orphan diseases as well as examines the regulatory framework, patents, and recent innovations in the industry. The report also analyzes each submarket and its applications, projections, and market shares. Technological issues include the latest trends and developments.
This report covers the regional segmentation included as North America, Europe, Asia-Pacific, and Rest of the World. This report also analyzes the regulatory framework for the clinical trials of orphan drugs in rare and orphan diseases. The report examines the trends and characteristics of clinical trials conducted on rare diseases from 1999-2018, using information from various sources. In addition, this report provides an overview of the global orphan drugs market and its competitive landscape. This report also examines acquisition strategies and collaborations, discusses the market’s strengths and weaknesses considering new technologies, and analyzes the industry’s growing competition and changing customer needs.
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2022 |
| Forecast period considered | 2023-2028 |
| Base year market size | $210.0 billion |
| Market size forecast | $415.2 billion |
| Growth rate | CAGR of 12.2% for the forecast period of 2023-2028 |
| Units considered | $ Millions |
| Segments covered | Product Type, Therapeutic Application, Region |
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) |
| Countries covered | U.S., Canada, Mexico, Spain, Italy, Netherlands, Turkey, Austria, Poland, Germany, UK, France, China, India, Japan, Australia, South Korea, Thailand, Singapore, Vietnam, Middle East and Africa |
| Key Market Drivers | Favorable Orphan Drug Act and Similar Legislation Technological Advances in Genomics Lack of Competition from Generic Drugs Patent Extensions Premium Pricing of Orphan Drugs Innovations in Manufacturing Technologies Increasing Collaborations and Licensing Agreements |
| Companies studied | ABBVIE INC. ASTELLAS PHARMA INC. ASTRAZENECA PLC BRISTOL MYERS SQUIBB EISAI CO. LTD. ELI LILLY AND CO. F. HOFFMANN-LA ROCHE LTD. MERCK & CO. INC. NOVARTIS AG PFIZER INC. SANOFI S.A. TAKEDA PHARMACEUTICAL CO. LTD. |